A comparative study of the ReCell® device and autologous split-thickness meshed skin graft in the treatment of acute burn injuries

James Hill Holmes, Joseph A. Molnar, Jeffrey E. Carter, James Hwang, Bruce A. Cairns, Booker T. King, David J. Smith, C. Wayne Cruse, Kevin N. Foster, Michael D. Peck, Rajiv Sood, Michael J. Feldman, Marion H. Jordan, David W. Mozingo, David G. Greenhalgh, Tina L. Palmieri, John A. Griswold, Sharmila Dissanaike, William L. Hickerson

Research output: Contribution to journalArticle

Abstract

Early excision and autografting are standard care for deeper burns. However, donor sites are a source of significant morbidity. To address this, the ReCell® Autologous Cell Harvesting Device (ReCell) was designed for use at the point-of-care to prepare a noncultured, autologous skin cell suspension (ASCS) capable of epidermal regeneration using minimal donor skin. A prospective study was conducted to evaluate the clinical performance of ReCell vs meshed split-thickness skin grafts (STSG, Control) for the treatment of deep partial-thickness burns. Effectiveness measures were assessed to 1 year for both ASCS and Control treatment sites and donor sites, including the incidence of healing, scarring, and pain. at 4 weeks, 98% of the ASCS-treated sites were healed compared with 100% of the Controls. Pain and assessments of scarring at the treatment sites were reported to be similar between groups. Significant differences were observed between ReCell and Control donor sites. The mean ReCell donor area was approximately 40 times smaller than that of the Control (P < .0001), and after 1 week, significantly more ReCell donor sites were healed than Controls (P = .04). Over the first 16 weeks, patients reported significantly less pain at the ReCell donor sites compared with Controls (P ≤ .05 at each time point). Long-term patients reported higher satisfaction with ReCell donor site outcomes compared with the Controls. This study provides evidence that the treatment of deep partial-thickness burns with ASCS results in comparable healing, with significantly reduced donor site size and pain and improved appearance relative to STSG. (J Burn Care Res 2018;39:694–702)

LanguageEnglish (US)
Pages694-702
Number of pages9
JournalJournal of Burn Care and Research
Volume39
Issue number5
DOIs
StatePublished - Jan 1 2018

Fingerprint

Tissue Donors
Transplants
Equipment and Supplies
Skin
Wounds and Injuries
Suspensions
Burns
Therapeutics
Pain
Cicatrix
Point-of-Care Systems
Autologous Transplantation
Pain Measurement
Regeneration
Prospective Studies
Morbidity
Incidence

ASJC Scopus subject areas

  • Surgery
  • Emergency Medicine
  • Rehabilitation

Cite this

Holmes, J. H., Molnar, J. A., Carter, J. E., Hwang, J., Cairns, B. A., King, B. T., ... Hickerson, W. L. (2018). A comparative study of the ReCell® device and autologous split-thickness meshed skin graft in the treatment of acute burn injuries. Journal of Burn Care and Research, 39(5), 694-702. https://doi.org/10.1093/jbcr/iry029

A comparative study of the ReCell® device and autologous split-thickness meshed skin graft in the treatment of acute burn injuries. / Holmes, James Hill; Molnar, Joseph A.; Carter, Jeffrey E.; Hwang, James; Cairns, Bruce A.; King, Booker T.; Smith, David J.; Wayne Cruse, C.; Foster, Kevin N.; Peck, Michael D.; Sood, Rajiv; Feldman, Michael J.; Jordan, Marion H.; Mozingo, David W.; Greenhalgh, David G.; Palmieri, Tina L.; Griswold, John A.; Dissanaike, Sharmila; Hickerson, William L.

In: Journal of Burn Care and Research, Vol. 39, No. 5, 01.01.2018, p. 694-702.

Research output: Contribution to journalArticle

Holmes, JH, Molnar, JA, Carter, JE, Hwang, J, Cairns, BA, King, BT, Smith, DJ, Wayne Cruse, C, Foster, KN, Peck, MD, Sood, R, Feldman, MJ, Jordan, MH, Mozingo, DW, Greenhalgh, DG, Palmieri, TL, Griswold, JA, Dissanaike, S & Hickerson, WL 2018, 'A comparative study of the ReCell® device and autologous split-thickness meshed skin graft in the treatment of acute burn injuries' Journal of Burn Care and Research, vol. 39, no. 5, pp. 694-702. https://doi.org/10.1093/jbcr/iry029
Holmes, James Hill ; Molnar, Joseph A. ; Carter, Jeffrey E. ; Hwang, James ; Cairns, Bruce A. ; King, Booker T. ; Smith, David J. ; Wayne Cruse, C. ; Foster, Kevin N. ; Peck, Michael D. ; Sood, Rajiv ; Feldman, Michael J. ; Jordan, Marion H. ; Mozingo, David W. ; Greenhalgh, David G. ; Palmieri, Tina L. ; Griswold, John A. ; Dissanaike, Sharmila ; Hickerson, William L. / A comparative study of the ReCell® device and autologous split-thickness meshed skin graft in the treatment of acute burn injuries. In: Journal of Burn Care and Research. 2018 ; Vol. 39, No. 5. pp. 694-702.
@article{127971b7de2a40348d4072ca16177617,
title = "A comparative study of the ReCell{\circledR} device and autologous split-thickness meshed skin graft in the treatment of acute burn injuries",
abstract = "Early excision and autografting are standard care for deeper burns. However, donor sites are a source of significant morbidity. To address this, the ReCell{\circledR} Autologous Cell Harvesting Device (ReCell) was designed for use at the point-of-care to prepare a noncultured, autologous skin cell suspension (ASCS) capable of epidermal regeneration using minimal donor skin. A prospective study was conducted to evaluate the clinical performance of ReCell vs meshed split-thickness skin grafts (STSG, Control) for the treatment of deep partial-thickness burns. Effectiveness measures were assessed to 1 year for both ASCS and Control treatment sites and donor sites, including the incidence of healing, scarring, and pain. at 4 weeks, 98{\%} of the ASCS-treated sites were healed compared with 100{\%} of the Controls. Pain and assessments of scarring at the treatment sites were reported to be similar between groups. Significant differences were observed between ReCell and Control donor sites. The mean ReCell donor area was approximately 40 times smaller than that of the Control (P < .0001), and after 1 week, significantly more ReCell donor sites were healed than Controls (P = .04). Over the first 16 weeks, patients reported significantly less pain at the ReCell donor sites compared with Controls (P ≤ .05 at each time point). Long-term patients reported higher satisfaction with ReCell donor site outcomes compared with the Controls. This study provides evidence that the treatment of deep partial-thickness burns with ASCS results in comparable healing, with significantly reduced donor site size and pain and improved appearance relative to STSG. (J Burn Care Res 2018;39:694–702)",
author = "Holmes, {James Hill} and Molnar, {Joseph A.} and Carter, {Jeffrey E.} and James Hwang and Cairns, {Bruce A.} and King, {Booker T.} and Smith, {David J.} and {Wayne Cruse}, C. and Foster, {Kevin N.} and Peck, {Michael D.} and Rajiv Sood and Feldman, {Michael J.} and Jordan, {Marion H.} and Mozingo, {David W.} and Greenhalgh, {David G.} and Palmieri, {Tina L.} and Griswold, {John A.} and Sharmila Dissanaike and Hickerson, {William L.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1093/jbcr/iry029",
language = "English (US)",
volume = "39",
pages = "694--702",
journal = "Journal of Burn Care and Research",
issn = "1559-047X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - A comparative study of the ReCell® device and autologous split-thickness meshed skin graft in the treatment of acute burn injuries

AU - Holmes, James Hill

AU - Molnar, Joseph A.

AU - Carter, Jeffrey E.

AU - Hwang, James

AU - Cairns, Bruce A.

AU - King, Booker T.

AU - Smith, David J.

AU - Wayne Cruse, C.

AU - Foster, Kevin N.

AU - Peck, Michael D.

AU - Sood, Rajiv

AU - Feldman, Michael J.

AU - Jordan, Marion H.

AU - Mozingo, David W.

AU - Greenhalgh, David G.

AU - Palmieri, Tina L.

AU - Griswold, John A.

AU - Dissanaike, Sharmila

AU - Hickerson, William L.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Early excision and autografting are standard care for deeper burns. However, donor sites are a source of significant morbidity. To address this, the ReCell® Autologous Cell Harvesting Device (ReCell) was designed for use at the point-of-care to prepare a noncultured, autologous skin cell suspension (ASCS) capable of epidermal regeneration using minimal donor skin. A prospective study was conducted to evaluate the clinical performance of ReCell vs meshed split-thickness skin grafts (STSG, Control) for the treatment of deep partial-thickness burns. Effectiveness measures were assessed to 1 year for both ASCS and Control treatment sites and donor sites, including the incidence of healing, scarring, and pain. at 4 weeks, 98% of the ASCS-treated sites were healed compared with 100% of the Controls. Pain and assessments of scarring at the treatment sites were reported to be similar between groups. Significant differences were observed between ReCell and Control donor sites. The mean ReCell donor area was approximately 40 times smaller than that of the Control (P < .0001), and after 1 week, significantly more ReCell donor sites were healed than Controls (P = .04). Over the first 16 weeks, patients reported significantly less pain at the ReCell donor sites compared with Controls (P ≤ .05 at each time point). Long-term patients reported higher satisfaction with ReCell donor site outcomes compared with the Controls. This study provides evidence that the treatment of deep partial-thickness burns with ASCS results in comparable healing, with significantly reduced donor site size and pain and improved appearance relative to STSG. (J Burn Care Res 2018;39:694–702)

AB - Early excision and autografting are standard care for deeper burns. However, donor sites are a source of significant morbidity. To address this, the ReCell® Autologous Cell Harvesting Device (ReCell) was designed for use at the point-of-care to prepare a noncultured, autologous skin cell suspension (ASCS) capable of epidermal regeneration using minimal donor skin. A prospective study was conducted to evaluate the clinical performance of ReCell vs meshed split-thickness skin grafts (STSG, Control) for the treatment of deep partial-thickness burns. Effectiveness measures were assessed to 1 year for both ASCS and Control treatment sites and donor sites, including the incidence of healing, scarring, and pain. at 4 weeks, 98% of the ASCS-treated sites were healed compared with 100% of the Controls. Pain and assessments of scarring at the treatment sites were reported to be similar between groups. Significant differences were observed between ReCell and Control donor sites. The mean ReCell donor area was approximately 40 times smaller than that of the Control (P < .0001), and after 1 week, significantly more ReCell donor sites were healed than Controls (P = .04). Over the first 16 weeks, patients reported significantly less pain at the ReCell donor sites compared with Controls (P ≤ .05 at each time point). Long-term patients reported higher satisfaction with ReCell donor site outcomes compared with the Controls. This study provides evidence that the treatment of deep partial-thickness burns with ASCS results in comparable healing, with significantly reduced donor site size and pain and improved appearance relative to STSG. (J Burn Care Res 2018;39:694–702)

UR - http://www.scopus.com/inward/record.url?scp=85055649859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055649859&partnerID=8YFLogxK

U2 - 10.1093/jbcr/iry029

DO - 10.1093/jbcr/iry029

M3 - Article

VL - 39

SP - 694

EP - 702

JO - Journal of Burn Care and Research

T2 - Journal of Burn Care and Research

JF - Journal of Burn Care and Research

SN - 1559-047X

IS - 5

ER -